Strategic Partnership with FILLMED UK to Accelerate Expansion into UK and Ireland

Strategic Partnership with FILLMED UK to Accelerate Expansion into UK and Ireland

VAIM Co., Ltd. is proud to announce a strategic partnership with FILLMED UK, appointing them as the official distributor of Juvelook and Lenisna in the United Kingdom and Ireland. In collaboration with their trusted partner, Church Pharmacy, FILLMED UK will supply our innovative products to medical professionals across both regions.

This partnership marks a significant milestone in VAIM’s global expansion, grounded in a shared commitment to scientific innovation and the delivery of safe, effective aesthetic solutions. Through FILLMED UK’s established commercial and marketing infrastructure, local professionals will now have direct access to Juvelook and Lenisna, our next-generation hybrid biostimulators known for their proven clinical efficacy and unique formulation. JUVELOOK has made waves, winning Best Injectable for Skin Revitalization at AMWC Monaco 2025, a testament to its breakthrough potential.

By combining VAIM’s advanced technologies with FILLMED UK’s deep market expertise, this collaboration will accelerate the adoption and growth of Juvelook and Lenisna in the UK and Ireland. Together, we aim to enhance localized product strategies, clinical support, and marketing initiatives tailored specifically to these dynamic and fast-evolving markets.

We look forward to a successful partnership and continued advancement in the field of medical aesthetics.

Please note: Complaints or issues related to products not purchased through the official distribution channel may not be supported.

For the safety of both patients and practitioners, we strongly advise purchasing and getting trainings only through our Official distributors.

✔ For inquiries and orders in the UK and Ireland: FILLMED UK or Church Pharmacy

Introduction of VAIM
Founded in 2014, VAIM is a global medical aesthetics company that develops human tissue regeneration products and improved pharmaceuticals by utilizing its accumulated technology and know-how in biocompatible and biodegradable polymers. It has developed and patented a PDLLA-based manufacturing technology that reduces the risk of nodule formation compared to other ingredient structures, and in 2019, its subsidiary, VAIM, entered the skin booster market with JUVELOOK, which utilizes this technology. JUVELOOK is a collagen booster that induces the production of ECM (collagen, elastin) to provide direct remodeling effects on the skin such as elasticity and wrinkle improvement, and is divided into JUVELOOK and LENISNA depending on the purpose. After quickly proving its safety and effectiveness since its launch, VAIM currently has product export contracts with 72 countries.